NCT06546384Not yet recruiting
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
There is evidence that alcoholic beverage consumption significantly interacts with food energy intake. Furthermore, there is accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic factors on the onset and progression of chronic liver disease. Preclinical and clinical data have showed that GLP-1 RA can decrease alcohol consumption, particularly in obese patients. Moreover there is evidence that semaglutide can improve the liver sinusoidal milieu in pre-clinical models of cirrhosis. In this study, the investigators aim to assess if patients treated with semaglutide and receiving counselling will achieve a significantly higher alcohol abstinence compared to patients only receiving counselling.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- First submitted
- 6 Aug 2024
- Start date
- 1 Nov 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Diseases
- Obesity, Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06546384
What you commit to
- Study type: Interventional
- Planned participants: 64
- From 1 Nov 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current treatment with drugs against alcohol dependence (disulfiram, acamprosate, naltrexone, baclofen and nalmefene)
- Presence or history of a hepatic or extrahepatic malignancy from the previous 6 months
Other
- Active illicit substance use
- AUDIT-score \< 5 (males)/ 4 (females) (as measured from AUDIT-questionnaire distributed in visit 1)
- Any known contraindication to semaglutide
Who the study is looking for
- BMI ≥ 35 kg/m² OR BMI ≥ 28 kg/m² in the case of weight-related co-morbidities (pre-diabetes or type 2 diabetes mellitus, hypertension, dyslipidemia).
- Fatty liver disease (steatosis on ultrasound and/or CAP value on FS \> 238 dB/m)
- Age 18 - 80 years
- Alcohol Use Disorder Identification Test-C Score \>4 (AUDIT-C) Score ≥4 for women and ≥5 for men (as measured from AUDIT-questionnaire distributed in visit 1)
- Sufficient skills for German or French language (written and spoken)
- Signed informed consent
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Bern Coordinator of this site? Confirm its status | Bern | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.